Randomized open trial for comparison of proton pump inhibitors in triple therapy for <i>Helicobacter pylori</i> infection in relation to <i>CYP2C19</i> genotype

200276 citationsJournal Article

Authors

Tomoki Inaba · Kagawa Prefectural Central Hospital

Motowo Mizuno

Kozou Kawai · Kagawa Prefectural Central Hospital

Kenji Yokota · Okayama University

Keiji Oguma · Okayama University

Abstract

The overall cure rate of 1-week triple therapy for H. pylori eradication was not significantly different between regimens with omeprazole, lansoprazole or rabeprazole, but the impact of CYP2C19 genetic polymorphism on the cure rate appeared to differ between these PPI.

Topics & Keywords

Helicobacter pylori-related gastroenterology studies Gastroesophageal reflux and treatments Veterinary medicine and infectious diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Gastroenterology and Hepatology

Volume 17, Issue 7, pp. 748-753

DOI: 10.1046/j.1440-1746.2002.02790.x

Field-Weighted Citation Impact: 4.78